Details of the Drug Combination

General Information of Drug Combination (ID: DC2M4QD)

Drug Combination Name
MK-5108 MK-1775
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs MK-5108   DMFGYKS MK-1775   DM3WDZ5
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HCT116
Zero Interaction Potency (ZIP) Score: 2.04
Bliss Independence Score: 0.78
Loewe Additivity Score: 1.91
LHighest Single Agent (HSA) Score: 6.07

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-5108
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
MK-5108 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aurora kinase B (AURKB) TT5LS6T AURKB_HUMAN Inhibitor [5]
Aurora kinase A (AURKA) TTPS3C0 AURKA_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of MK-1775
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
MK-1775 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Wee1-like protein kinase (WEE1) TTJFOAL WEE1_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
MK-1775 Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Phosphorylation [6]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Response To Substance [6]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCDQSUA ES2 Investigative [7]
Breast carcinoma DCRX11K OCUBM Investigative [8]
Carcinoma DC56HD2 MDAMB436 Investigative [8]
Colon carcinoma DCABBSQ RKO Investigative [8]
Invasive ductal carcinoma DCYYN7D T-47D Investigative [8]
Rectal adenocarcinoma DCUSAYP SW837 Investigative [8]
Adenocarcinoma DCOXEVO CAOV3 Investigative [1]
Adenocarcinoma DC44MSQ OVCAR3 Investigative [1]
Adenocarcinoma DCSO3XW A427 Investigative [1]
Adenocarcinoma DCC7BQ6 NCIH2122 Investigative [1]
Adenocarcinoma DCN623R NCIH23 Investigative [1]
Adenocarcinoma DCGQ7NR COLO320DM Investigative [1]
Adenocarcinoma DCUWAYC HT29 Investigative [1]
Adenocarcinoma DCBPBOT SW-620 Investigative [1]
Amelanotic melanoma DCFA5RP A2058 Investigative [1]
Germ cell tumour DCIUM2S PA1 Investigative [1]
Malignant melanoma DCFSZYW A375 Investigative [1]
Malignant melanoma DCE0O1S RPMI7951 Investigative [1]
Malignant melanoma DCH60AA SKMEL30 Investigative [1]
Malignant melanoma DC45SSS UACC62 Investigative [1]
Ovarian endometrioid adenocarcinoma DCBDDWF A2780 Investigative [1]
Ovarian serous cystadenocarcinoma DC7SDXK SK-OV-3 Investigative [1]
Prostate carcinoma DC3W8HM VCAP Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT00543387) Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4). U.S. National Institutes of Health.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
6 Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.
7 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
8 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.